“Efficacy and Safety of Bimekizumab in Patients With Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study With Randomized Withdrawal”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 6, Oct. 2020, p. s83, https://doi.org/10.25251/skin.4.supp.83.